27/07/2022 (Agence Europe) – On 22 July, the European Medicines Agency (EMA) initiated an evaluation of two SARS-CoV-2 vaccines adapted to a new variant of concern. The evaluation concerns the adapted forms of two mRNA vaccines that already have a conditional marketing authorisation: the Comirnaty vaccine developed by the Pfizer-BioNTech companies and the Spikevax vaccine developed by the Moderna company. The two companies have each proposed a bivalent mRNA vaccine tailored to the...